## Andrew F Auld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/43031/publications.pdf

Version: 2024-02-01

43 902 18 29
papers citations h-index g-index

45 45 45 1533 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. The Lancet Global Health, 2022, 10, e705-e714.	2.9	4
2	Prevalence of and factors associated with late diagnosis of HIV in Malawi, Zambia, and Zimbabwe: Results from population-based nationally representative surveys. PLOS Global Public Health, 2022, 2, e0000080.	0.5	7
3	Early post-partum viremia predicts long-term non-suppression of viral load in HIV-positive women on ART in Malawi: Implications for the elimination of infant transmission. PLoS ONE, 2021, 16, e0248559.	1.1	6
4	Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). PLoS ONE, 2021, 16, e0248115.	1.1	2
5	Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A cohort study. PLoS Medicine, 2021, 18, e1003739.	3.9	4
6	The National Evaluation of Malawi's PMTCT Program (NEMAPP) study: 24â€month HIVâ€exposed infant outcomes from a prospective cohort study. HIV Medicine, 2021, , .	1.0	6
7	Risk scores for predicting early antiretroviral therapy mortality in sub-Saharan Africa to inform who needs intensification of care: a derivation and external validation cohort study. BMC Medicine, 2020, 18, 311.	2.3	O
8	Outcomes of HIV-positive patients with non-tuberculous mycobacteria positive culture who received anti-tuberculous treatment in Botswana: Implications of using diagnostic algorithms without non-tuberculous mycobacteria. PLoS ONE, 2020, 15, e0234646.	1.1	1
9	Effect of tuberculosis screening and retention interventions on early antiretroviral therapy mortality in Botswana: a stepped-wedge cluster randomized trial. BMC Medicine, 2020, 18, 19.	2.3	5
10	Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 643-650.	0.9	4
11	The effect of sputum quality and volume on the yield of bacteriologically-confirmed TB by Xpert MTB/RIF and smear. Pan African Medical Journal, 2019, 33, 110.	0.3	4
12	Low detectable postpartum viral load is associated with HIV transmission in Malawi's prevention of motherâ€toâ€child transmission programme. Journal of the International AIDS Society, 2019, 22, e25290.	1.2	24
13	Childhood Violence Is Associated with Forced Sexual Initiation Among Girls and Young Women in Malawi: A Cross-Sectional Survey. Journal of Pediatrics, 2019, 208, 265-272.e1.	0.9	7
14	Mozambique's Community Antiretroviral Therapy Support Group Program: The Role of Social Relationships in Facilitating HIV/AIDS Treatment Retention. AIDS and Behavior, 2019, 23, 2477-2485.	1.4	7
15	Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial. BMC Infectious Diseases, 2019, 19, 1058.	1.3	6
16	Scaling Up Testing for Human Immunodeficiency Virus Infection Among Contacts of Index Patients — 20 Countries, 2016–2018. Morbidity and Mortality Weekly Report, 2019, 68, 474-477.	9.0	29
17	National estimates and risk factors associated with early mother-to-child transmission of HIV after implementation of option B+: a cross-sectional analysis. Lancet HIV,the, 2018, 5, e688-e695.	2.1	40
18	Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure. Journal of the Pediatric Infectious Diseases Society, 2018, 9, 6-13.	0.6	4

#	Article	IF	CITATIONS
19	Incidence and predictors of tuberculosis among HIV-infected adults after initiation of antiretroviral therapy in Nigeria, 2004-2012. PLoS ONE, 2017, 12, e0173309.	1.1	27
20	Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay. PLoS ONE, 2017, 12, e0189981.	1.1	25
21	High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004–2012. PLoS ONE, 2017, 12, e0183823.	1.1	15
22	Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment — 10 Countries, 2004–2015. Morbidity and Mortality Weekly Report, 2017, 66, 558-563.	9.0	34
23	Retention Throughout the HIV Care and Treatment Cascade: From Diagnosis to Antiretroviral Treatment of Adults and Children Living with HIV—Haiti, 1985–2015. American Journal of Tropical Medicine and Hygiene, 2017, 97, 57-70.	0.6	13
24	Community ART Support Groups in Mozambique: The Potential of Patients as Partners in Care. PLoS ONE, 2016, 11, e0166444.	1.1	40
25	Decentralizing Access to Antiretroviral Therapy for Children Living with HIV in Swaziland. Pediatric Infectious Disease Journal, 2016, 35, 886-893.	1.1	5
26	Variation in attrition at subnational level: review of the <scp>B</scp> otswana <scp>N</scp> ational <scp>HIV</scp> / <scp>AIDS T</scp> reatment ( <scp>M</scp> asa) programme data (2002–2013). Tropical Medicine and International Health, 2016, 21, 18-27.	1.0	5
27	Xpert MTB/RIF ― why the lack of morbidity and mortality impact in intervention trials?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 432-444.	0.7	50
28	Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana's Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality. BMC Infectious Diseases, 2016, 16, 606.	1.3	14
29	A Decade of Antiretroviral Therapy Scale-up in Mozambique: Evaluation of Outcome Trends and New Models of Service Delivery Among More Than 300,000 Patients Enrolled During 2004—2013. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e11-e22.	0.9	43
30	Wide Variations in Compliance with Tuberculosis Screening Guidelines and Tuberculosis Incidence between Antiretroviral Therapy Facilities — Cà te d'Ivoire. PLoS ONE, 2016, 11, e0157059.	1,1	6
31	Outcomes of Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Treatment between 2004-2012. PLoS ONE, 2016, 11, e0165528.	1.1	43
32	Temporal Trends in Patient Characteristics and Outcomes Among Children Enrolled in Mozambique's National Antiretroviral Therapy Program. Pediatric Infectious Disease Journal, 2015, 34, e191-e199.	1.1	8
33	Retention and Risk Factors for Loss to Follow-up of Female and Male Sex Workers on Antiretroviral Treatment in Ivory Coast. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, S99-S106.	0.9	17
34	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, e1-e12.	0.9	17
35	Trends and determinants of survival for over 200 000 patients on antiretroviral treatment in the Botswana National Program. Aids, 2015, 30, 1.	1.0	32
36	Lower Levels of Antiretroviral Therapy Enrollment Among Men with HIV Compared with Women — 12 Countries, 2002–2013. Morbidity and Mortality Weekly Report, 2015, 64, 1281-1286.	9.0	41

#	Article	IF	CITATIONS
37	Temporal Trends in Mortality and Loss to Follow-up Among Children Enrolled in Côte d'Ivoire's National Antiretroviral Therapy Program. Pediatric Infectious Disease Journal, 2014, 33, 1134-1140.	1.1	20
38	Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia. Tropical Medicine and International Health, 2014, 19, 1397-1410.	1.0	64
39	Temporal Trends in Treatment Outcomes for HIV-1 and HIV-2-Infected Adults Enrolled in Côte d'Ivoire's National Antiretroviral Therapy Program. PLoS ONE, 2014, 9, e98183.	1.1	21
40	Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults—seven African countries, 2004-2013. Morbidity and Mortality Weekly Report, 2014, 63, 1097-103.	9.0	84
41	Incidence and Determinants of Tuberculosis among Adults Initiating Antiretroviral Therapy – Mozambique, 2004–2008. PLoS ONE, 2013, 8, e54665.	1.1	31
42	Four-Year Treatment Outcomes of Adult Patients Enrolled in Mozambique's Rapidly Expanding Antiretroviral Therapy Program. PLoS ONE, 2011, 6, e18453.	1.1	81
43	Piloting the use of personal digital assistants for tuberculosis and human immunodeficiency virus surveillance, Kenya, 2007. International Journal of Tuberculosis and Lung Disease, 2010, 14, 1140-6.	0.6	3